Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration

References

• Kaae S, Johansen H. Does simple mastectomy followed by irradiation offer survival comparable to radical procedures? Int J Radiat Oncol Biol Phys. 1977;2:1163–1166.
   PubMed Web of Science ®Google Scholar
• McWhirter R. Simple mastectomy and radiotherapy in the treatment of breast cancer. Br J Radiol. 1955;28:128–139.
   PubMed Web of Science ®Google Scholar
• Dahl-Iversen E, Toiassen T. Radical mastectomy with parasternal and supraclavicular dissection for mammary carcinoma. Ann Surg. 1963;157:170–173.
   PubMed Web of Science ®Google Scholar
• Johansen H, Kaae S, Johansen H, et al. Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen breast cancer randomised study. Acta Oncol. 2008;47:633–638.
   PubMed Web of Science ®Google Scholar
• McWhirter R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. BJR. 1948;21:99–610.
   PubMed Web of Science ®Google Scholar
• Ellis F. Dose, time and fractionation: A clinical hypothesis. Clin Radiol. 1969;20:1–7.
   PubMedGoogle Scholar
• Bentzen S, Overgaard M. Early and late normal tissue injury after postmastectomy radiotherapy. Recent Results Cancer Res. 1993;130:59–78.
   PubMedGoogle Scholar
• Fisher B. Laboratory and clinical research in breast cancer – a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980;40:3863–3874.
   PubMed Web of Science ®Google Scholar
• Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46:1.
   PubMedGoogle Scholar
• Overgaard M, Hansen PS, Overgaard J, Danish Breast Cancer Cooperative Group 82b Trial, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–955.
   PubMed Web of Science ®Google Scholar
• Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish breast cancer cooperative group DBCG 82c randomised trial. Lancet. 1999;353:1641–1648.
   PubMed Web of Science ®Google Scholar
• Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–253.
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish breast cancer cooperative group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–2275.
   PubMed Web of Science ®Google Scholar
• McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–2135.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700–1712.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Brincker H, Andersen JA, et al. A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results. Acta Oncol. 1988;27:671–677.
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Nielsen M, Düring M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47:672–681.
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106.
   PubMed Web of Science ®Google Scholar
• Christiansen PM, Carstensen SL, Ejlertsen B, et al. Breast conserving surgery versus mastectomy: overall and relative survival – a population based study by the Danish breast cancer cooperative group. Acta Oncol. 2017 [Nov 23]; [7 p.]. DOI:10.1080/0284186X.2017.1403042
   Web of Science ®Google Scholar
• Langhans L, Jensen MB, Talman MM, et al. Reoperation rates in ductal carcinoma in situ vs invasive breast cancer after wire-guided breast-conserving surgery. JAMA Surg. 2017;152:378–384.
   PubMed Web of Science ®Google Scholar
• Langhans L, Tvedskov TF, Klausen TL, et al. Radioactive seed localization or wire-guided localization of nonpalpable invasive and in situ breast cancer: a randomized, multicenter, open-label trial. Ann Surg. 2017;266:29–35.
   PubMed Web of Science ®Google Scholar
• Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–1150.
   PubMedGoogle Scholar
• Bentzen SM, Agrawal RK, Aird EG, START Trialists’ Group, et al. The UK standardisation of breast radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–1107.
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Friis RB, Linnet S, et al. Loco-regional morbidity after breast conservation and axillary lymph node dissection for early breast cancer with or without regional nodes radiotherapy, perspectives in modern breast cancer treatment: the Skagen Trial 1 is active. Acta Oncol. 2017;56:713–718.
   PubMed Web of Science ®Google Scholar
• Francolini G, Thomsen MS, Yates ES, et al. Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiother Oncol. 2017;123:282–287.
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Arenas M, Livi L. Over-irradiation. Breast. 2017;31:295–302.
   PubMed Web of Science ®Google Scholar
• Offersen BV, Overgaard M, Kroman N, et al. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol. 2009;90:1–13.
   PubMed Web of Science ®Google Scholar
• Coles CE, Griffin CL, Kirby AM, IMPORT Trialists, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UKIMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–1060.
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–327.
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:1878–1879.
   PubMed Web of Science ®Google Scholar
• Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314–320.
   PubMed Web of Science ®Google Scholar
• Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–1310.
   PubMed Web of Science ®Google Scholar
• Friis E, Galatius H, Garne JP. Organized nation-wide implementation of sentinel lymph node biopsy in Denmark. Acta Oncol. 2008;47:556–560.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Friis E, Balslev E, et al. Sentinel node biopsy in breast cancer: five years experience from Denmark. Acta Oncol. 2008;47:561–568.
   PubMed Web of Science ®Google Scholar
• Husted Madsen A, Haugaard K, Soerensen J, et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish breast cancer cooperative group. Breast. 2008;17:138–147.
   PubMed Web of Science ®Google Scholar
• de Boniface J, Frisell J, Andersson Y, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer. 2017;17:379.
   PubMed Web of Science ®Google Scholar
• Lyngholm CD, Laurberg T, Alsner J, et al. Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort. Acta Oncol. 2016;55:983–992.
   PubMed Web of Science ®Google Scholar
• Lyngholm CD, Christiansen PM, Damsgaard TE, et al. Long-term follow-up of late morbidity, cosmetic outcome and body image after breast conserving therapy. A study from the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol. 2013;52:259–269.
   PubMed Web of Science ®Google Scholar
• Laurberg T, Lyngholm CD, Christiansen PM, et al. Long-term age-dependent failure pattern after breast-conserving therapy or mastectomy among Danish lymph-node-negative breast cancer patients. Radiother Oncol. 2016;120:98–106.
   PubMed Web of Science ®Google Scholar
• Laurberg T, Alsner J, Tramm T, et al. Impact of age, intrinsic subtype and local treatment on long-term locol-regional recurrence and breast cancer mortality among low-risk breast cancer patients. Acta Oncol. 2017;56:59–67.
   PubMed Web of Science ®Google Scholar
• Tramm T, Kyndi M, Myhre S, et al. Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. Acta Oncol. 2014;53:1337–1346.
   PubMed Web of Science ®Google Scholar
• Tramm T, Mohammed H, Myhre S, et al. Development and validation of a gene profile predicting benefit from postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG 82 b&c cohort. Clin Can Res. 2014;20:5272–5280.
   PubMed Web of Science ®Google Scholar
• Højris I, Andersen J, Overgaard M, et al. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic therapy versus systemic therapy alone. Acta Oncol. 2000;39:355–372.
   PubMed Web of Science ®Google Scholar
• Kyndi M, Overgaard M, Nielsen HM, et al. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol. 2009;90:74–79.
   PubMed Web of Science ®Google Scholar
• Højris I, Overgaard M, Christensen JJ, et al. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomized trials. Lancet. 1999;354:1425–1430.
   PubMed Web of Science ®Google Scholar
• McGale P, Darby S, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100:167–175.
   PubMed Web of Science ®Google Scholar
• Darby S, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998.
   PubMed Web of Science ®Google Scholar
• Taylor C, Correa C, Duane F, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. JCO. 2017;35:1641–1649.
   PubMed Web of Science ®Google Scholar
• Rehammar JC, Jensen MB, McGale P, et al. Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977–2005. Radiother Oncol. 2017;123:299–305.
   PubMed Web of Science ®Google Scholar
• Grantzau T, Thomsen MS, Vaeth M, et al. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiother Oncol. 2014;111:366–373.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Krarup JF, Palshof T, et al. Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. Acta Oncol. 2017 [Nov 22]; [5 p.]. DOI:10.1080/0284186X.2017.1400179
   Web of Science ®Google Scholar
• Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. JCO. 2001;19:3376–3384.
   PubMed Web of Science ®Google Scholar
• Knoop AS, Laenkholm AV, Jensen MB, Danish Breast Cancer Cooperative Group, et al. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer. 2014;50:1412–1421.
   PubMed Web of Science ®Google Scholar
• Andersen J, Kamby C, Ejlertsen B, et al. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol. 2008;47:718–724.
   PubMed Web of Science ®Google Scholar
• Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996;88:1543–1549.
   PubMed Web of Science ®Google Scholar
• Andersson M, Kamby C, Jensen MB, et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish breast cancer co-operative group DBCG 82B trial. Eur J Cancer. 1999;35:1659–1666.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681–1692.
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351:1451–1467.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–816.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(15_Suppl):5. DOI:10.1200/jco.2013.31.15_suppl.5
   PubMed Web of Science ®Google Scholar
• Brincker H, Rose C, Rank F, et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. JCO. 1987;5:1771–1778.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. JCO. 2006;24:4956–4962.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–1723.
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107–118.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–446.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Jensen MB, Mouridsen HT, et al. DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients. Acta Oncol. 2008;47:709–717.
   PubMed Web of Science ®Google Scholar
• Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol. 2013;121:709–716.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–1352.
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–776.
   PubMed Web of Science ®Google Scholar
• Regan MM, Neven P, Giobbie-Hurder A, BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG), et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011;12:1101–1108.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, Intergroup Exemestane Study, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092.
   PubMed Web of Science ®Google Scholar
• Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012;30:709–717.
   PubMed Web of Science ®Google Scholar
• Metzger Filho O, Giobbie-Hurder A, Mallon E, et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the big 1-98 trial. JCO. 2015;33:2772–2779.
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9:23–28.
   PubMed Web of Science ®Google Scholar
• Smith I, Yardley D, Burris H, et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial. JCO. 2017;35:1041–1048.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. JCO. 2013;31:1398–1404.
   PubMed Web of Science ®Google Scholar
• Colleoni M, Luo W, Karlsson P, et al. SOLE (Study of Letrozole Extension): a phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4–6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). J Clin Oncol. 2017;35(15_Suppl):503. DOI:10.1200/JCO.2017.35.15_suppl.503
   Web of Science ®Google Scholar
• Christiansen P, Bjerre K, Ejlertsen B, et al. Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst. 2011;103:1363–1372.
   PubMedGoogle Scholar
• Gianni L, Dafni U, Gelber RD, Herceptin Adjuvant (HERA) Trial Study Team, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–244.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. JCO. 2014;32:3744–3752.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–1283.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016;34:1034–1042.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–131.
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367–377.
   PubMed Web of Science ®Google Scholar
• Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2017 [Nov 13]. DOI:10.1016/S1470-2045(17)30717-9
   Web of Science ®Google Scholar
• Ejlertsen B. Adjuvant chemotherapy in early breast cancer. Dan Med J. 2016;63:pii:B5222.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, et al. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer. 2010;116:2081–2089.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Statement: Adjuvant Chemotherapy for Breast Cancer. September 9–11, 1985. CA Cancer J Clin. 1986;36:42–47.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Jensen MB, Burugu S, et al. High-risk, premenopausal luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: Results from the DBCG77B clinical trial. Clin Cancer Res. 2017;23:946–953.
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Rose C, Overgaard M, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncol. 1988;27:699–705.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Jensen MB, Elversang J, et al. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. Eur J Cancer. 2013;49:2986–2994.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta Oncol. 2008;47:662–671.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, et al. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer. 2007;43:877–884.
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.
   PubMed Web of Science ®Google Scholar
• Baxter J, Sen N, Martínez VL, et al. Positive supercoiling of mitotic DNA drives decatenation by topoisomerase II in eukaryotes. Science. 2011;331:1328–1332.
   PubMed Web of Science ®Google Scholar
• Kellner U, Sehested M, Jensen PB, et al. Culprit and victim – DNA topoisomerase II. Lancet Oncol. 2002;3:235–243.
   PubMed Web of Science ®Google Scholar
• Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483–7490.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 2011;12:1134–1142.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Tuxen MK, Jakobsen EH, et al. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. JCO. 2017;35:2639–2646.
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Jensen MB, Nielsen KV, et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. JCO. 2010;28:984–990.
   PubMed Web of Science ®Google Scholar
• Oakman C, Francis PA, Crown J, et al. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer–8-year results of the breast international group 02-98 phase III trial. Ann Oncol. 2013;24:1203–1211.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663–1671.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Ejlertsen B, Mouridsen HT, et al. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55:24–35.
   PubMed Web of Science ®Google Scholar
• Møller S, Jensen MB, Ejlertsen B, et al. The clinical database and the treatment guidelines of the Danish breast cancer cooperative group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506–524.
   PubMed Web of Science ®Google Scholar